← Back to Clinical Trials
Recruiting NCT06279689

NCT06279689 Echography Study_Anthropometric Measurements

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06279689
Status Recruiting
Phase
Sponsor Crossject
Condition Healthy Subjects
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2024-02-13
Primary Completion 2024-09

Eligibility & Interventions

Sex All sexes
Min Age 2 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Ultrasound scans

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2024-02-13 with a primary completion date of 2024-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a multi-center, exploratory, estimation study in both adult and pediatric populations. There is no investigational product injection during this study The exploratory objective of this study is to evaluate the anatomical characteristics of both anterolateral thighs in healthy adult and healthy pediatric populations (2 to 17 years old) by ultrasound scan before and while applying a force similar to the ZENEO® triggering force. In the healthy adult population, anatomical characteristics of one shoulder (deltoid) and one upper arm (biceps and triceps) will also be evaluated by ultrasound scan before and while applying a force similar to ZENEO® triggering force. Only ultrasound procedures will be performed using an investigational ultrasound system. All subjects will be asked to undergo 1 on site visit (Study Visit) during which the eligibility assessment and the ultrasound scans will be performed.

Eligibility Criteria

Inclusion Criteria: 1. Male or female, 2 to 70 years old, inclusive 2. In stable health, as determined by medical history and physical examination at screening (ie, any chronic medical diagnoses or conditions should be stable and well managed, with no significant changes expected during assessments, so that in the opinion of the investigator or designee there will not be any impact on the ability of the subject to participate in the study) 3. For the adult population, body mass index (BMI) ≥ 18.5 and ≤ 35 kg/m2 at screening BMI = weight (kg)/(height \[m\])2 4. Willing and able to provide written informed consent and assent (as appropriate) prior to initiation of study procedures 5. Subjects must be able to communicate effectively with the study staff and to understand study instructions (not applicable for toddlers and preschoolers) Exclusion Criteria: 1. Any skin or muscular condition, such as eczema, scars, infections, moles, or tattoos at the site of measurements 2. Allergy to ultrasound gel 3. Any other condition or prior therapy that, in the investigator or designee's opinion, would make the subject unsuitable for the study, or unable or unwilling to comply with the study procedures 4. Is an employee or authorized representative of CROSSJECT SA or ICON plc 5. Adult under guardianship or subject incarcerated

Contact & Investigator

Central Contact

Olivier LACOMBE

✉ o.lacombe@crossject.com

📞 +33617685235

Principal Investigator

Nathalie LOUGHRAIEB

STUDY DIRECTOR

Crossject

Frequently Asked Questions

Who can join the NCT06279689 clinical trial?

This trial is open to participants of all sexes, aged 2 Years or older, up to 70 Years, studying Healthy Subjects. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06279689 currently recruiting?

Yes, NCT06279689 is actively recruiting participants. Contact the research team at o.lacombe@crossject.com for enrollment information.

Where is the NCT06279689 trial being conducted?

This trial is being conducted at San Antonio, United States.

Who is sponsoring the NCT06279689 clinical trial?

NCT06279689 is sponsored by Crossject. The principal investigator is Nathalie LOUGHRAIEB at Crossject. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology